A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh(αK): A phase II study
Authors:
- 1 January 2020
- Vol. 38 (5) , 1048-1056
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Economic Affairs, ROC (106-EC-17-A22-I5-0-0010)
This publication has 30 references indexed in Scilit:
- Live Attenuated Influenza Vaccine (FluMist®; Fluenz™)Drugs, 2011
- A Novel Type of Influenza Vaccine: Safety and Immunogenicity of Replication‐Deficient Influenza Virus Created by Deletion of the Interferon Antagonist NS1The Journal of Infectious Diseases, 2010
- Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile ToxinPLOS ONE, 2009
- Enhancement of intranasal vaccination with recombinant chain A ricin vaccine (rRV) in mice by the mucosal adjuvants LTK63 and LTR72Vaccine, 2007
- Antibody responses after dose-sparing intradermal influenza vaccinationVaccine, 2007
- Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult VolunteersJournal of Virology, 2006
- Mucosal antibody response induced with a nasal virosome-based influenza vaccineVaccine, 2003
- Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxinVaccine, 1996
- New strategies for using mucosal vaccination to achieve more effective immunizationVaccine, 1994
- Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigensVaccine, 1988